Clinical trials
Injection clinical trials
Below are recruiting injection clinical trials, each written for real people, not researchers. We’re tracking 2,089 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07021677RecruitingPhase 2
Daratumumab for leftover leukemia cells after T-ALL treatment
This trial tests if adding the drug daratumumab can clear remaining cancer cells in people with T-cell acute lymphoblastic leukemia (T-ALL) who still have a small amount of leukemia after initial chemotherapy. It aims to reduce the risk of the cancer coming back.
Navi Mumbai, MaharashtraAges 18–65 - NCT07024173RecruitingPhase 3
Study of HRS-8080 for advanced breast cancer
This trial tests a new drug, HRS-8080, against other standard treatments chosen by your doctor for advanced or metastatic breast cancer. It's for women who have already tried 1-2 hormone therapies and are in generally good health.
Guangzhou, GuangdongAges 18–75 - NCT07025044Recruiting
Bladder microbiome study for women with overactive bladder getting Botox
This study looks at the bacteria in the bladders of women with overactive bladder who are getting Botox injections. It aims to understand how these bacteria might affect treatment results.
Washington D.C., District of ColumbiaAges 55 years+ - NCT07025408RecruitingPhase 2
Testing a new burn treatment for second-degree burns
This trial tests a new medicine called KJ101 for healing deep second-degree burns. It may help close the wound faster and reduce scarring.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07025642Recruiting
Overactive Bladder Treatments for Women
This study compares different treatments for overactive bladder in women in Taiwan. It aims to find the best approach to help control symptoms like frequent or urgent urination.
New Taipei CityAges 30–100 - NCT07029698RecruitingPhase 4
Vitamin shot vs. pill for B12 deficiency
This study tests whether a vitamin B12 injection is as safe and effective as a B12 pill. You may be able to join if you have low B12 levels and are not currently taking B12 supplements.
KharkivAges 18 years+ - NCT07030790RecruitingPhase 1
Single dose study of KLA480 in healthy volunteers
This trial tests a single dose of KLA480 in healthy adults to see how the body processes it. It may help researchers understand the drug's safety and potential benefits.
Shanghai, Shanghai MunicipalityAges 18–45 - NCT07036133RecruitingPhase 1
Study of Pralatrexate in patients with advanced cancer and liver problems
This trial tests a drug called pralatrexate in people with advanced solid tumors or blood cancers, including those with different levels of liver function. The goal is to understand how the drug works in the body and how safe it is for patients with various degrees of liver impairment.
Cerritos, CaliforniaAges 18 years+ - NCT07038382RecruitingPhase 2
Study of HLX79 with Rituximab for Active Kidney Disease
This trial tests a new drug called HLX79 (a human sialidase fusion protein) combined with rituximab, compared to a placebo, for people with active membranous nephropathy (a kidney disease). It aims to see if this combination can reduce protein in the urine and improve kidney function.
BeijingAges 18–75 - NCT07039526RecruitingPhase 2
Cytalux for finding cancer during surgery
This trial tests a dye called Cytalux that helps surgeons see cancer during surgery. You get the dye before surgery, and it makes cancer cells glow under a special light. This could help doctors remove more cancer.
Dallas, TexasAges 18 years+ - NCT07040930RecruitingPhase 1
Testing the safety of GenSci120 in healthy adults
This study tests a new drug called GenSci120, given as multiple injections under the skin, to see if it is safe in healthy adults. It will also measure how the drug moves through the body and how it affects certain immune markers.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT07051486RecruitingPhase 2
SHR-A1811 for HER2-positive recurrent or metastatic cervical cancer
This trial tests a new drug, SHR-A1811, that targets a protein called HER2 found on some cervical cancer cells. It's for women whose cervical cancer has returned or spread and is not responding to other treatments.
Fuzhou, FujianAges 18–75 - NCT07052383RecruitingPhase 1
DIT309 for advanced bone and soft tissue sarcomas
This trial tests a new cell therapy called DIT309 for people with advanced bone or soft tissue sarcoma that hasn't responded to standard treatments. It aims to see if this therapy is safe and effective.
Shanghai, Shanghai MunicipalityAges 8 years+ - NCT07052565Recruiting
CAR-T cell therapy for autoimmune diseases
This trial uses your own engineered immune cells (CAR-T cells) to treat severe autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, or systemic sclerosis that haven't improved with standard medicines. The goal is to see if this treatment can calm the immune system and reduce disease activity.
HefeiAges 18 years+ - NCT07058636Recruiting
Nerve block plus trigger point shots for neck pain relief
This study tests if adding a nerve block to standard trigger point injections provides better relief for people with chronic neck pain caused by myofascial pain syndrome.
AnkaraAges 18–65 - NCT07059169Recruiting
CAR-T cell therapy for severe autoimmune diseases
This trial tests a one-time CAR-T cell therapy for people with severe autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, dermatomyositis, or ANCA vasculitis. It aims to reset the immune system and reduce disease activity for those who haven't responded well to standard treatments.
Wuhan, HubeiAges 18 years+ - NCT07061288RecruitingPhase 1
Testing a new injectable medicine for schizophrenia
This trial tests a new injectable form of KarXT for schizophrenia. It aims to see if the medicine is safe, tolerable, and how it works in the body.
Los Alamitos, CaliforniaAges 18–55 - NCT07063030RecruitingEarly Phase 1
Gene therapy trial for AIPL1-related eye disease
This trial tests a gene therapy called LX107 for people with vision loss caused by changes in the AIPL1 gene. It aims to see if the treatment is safe and can improve vision.
ShanghaiAges 4 years+ - NCT07063199RecruitingPhase 2
Anti-CD38 antibody for older adults with hard-to-treat ITP
This trial tests an investigational antibody (anti-CD38) for older adults with ITP that hasn't improved with standard treatments. The goal is to see if this antibody can safely raise platelet counts and reduce bleeding risk.
Tianjin, Tianjin MunicipalityAges 60 years+ - NCT07068763RecruitingPhase 2
Short radiation plus drugs for early rectal cancer
This trial tests a combination of short-course radiation, chemotherapy (capecitabine), and two immunotherapy drugs (PD-1 and CTLA-4 inhibitors) for people with early-stage rectal cancer who want to avoid surgery and keep their anus. The goal is to see if this treatment can shrink the tumor enough to avoid major surgery.
Hangzhou, ZhejiangAges 18–80 - NCT07070050RecruitingPhase 4
NSAIDs after laparoscopic surgery: continuous or bolus?
This study compares giving NSAID pain relievers continuously through an IV versus as single doses (bolus) after laparoscopic surgery to find which method provides better pain relief with fewer side effects.
Moscow, Moscow OblastAges 18 years+ - NCT07071506Recruiting
New tools to track migraine prevention
This study tests new ways to monitor how well preventive migraine treatments are working. It is for people with chronic migraine who may be starting or already using preventive medications.
Aarhus C, DenmarkAges 18–65 - NCT07072169RecruitingPhase 1
Testing an mRNA therapy for relapsed B-cell lymphoma
This trial tests a new mRNA treatment that helps your immune cells target and attack lymphoma cells. It's for people whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07072247RecruitingPhase 1
RN1201 injection for hard-to-treat antibody-mediated blood disorders
This trial tests a new injection called RN1201 for people with antibody-mediated diseases, specifically two types of blood disorders: platelet transfusion refractoriness (PTR) and immune thrombocytopenia (ITP) that haven't responded to standard treatments. The goal is to see if RN1201 can help control these conditions.
Suzhou, JiangsuAges 16–65
Hear when a new Injection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for injection?
- Yes. Clin2 currently lists 2,089 recruiting injection studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a injection trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a injection trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.